Document:

EX-10.49

 Exhibit 10.49 

AMENDMENT AND TERMINATION 

OF THE 
 BIOVENTUS STOCK
PLAN 
 February 9, 2021 

Bioventus LLC, a Delaware limited liability company (the “Company”), has previously adopted the Bioventus Stock Plan
(previously known as the Bioventus LLC Phantom Profits Interests Plan), as amended and restated (and as may be amended from time to time, the “Plan”). Section 10 of the Plan allows the Board to amend the Plan in certain
respects from time to time. 
 The Board of Managers of the Company has determined that it is appropriate to amend and terminate the Plan
effective as of the date Bioventus Inc.’s registration statement on Form S-1 is declared effective, subject to the consummation of the initial public offering of Bioventus Inc. Class A Common Stock
(the “IPO”). In the event that the IPO is not consummated on or prior to December 31, 2021, this amendment and termination shall be void ab initio. 

The Plan, as revised by this amendment and termination, constitutes the entire Plan as amended to date. Capitalized terms not defined herein
shall have the meanings assigned to them under the Plan. Notwithstanding any other provision in the Plan: 
 1. Section 1(h) of the Plan is
hereby amended and restated in its entirety to read as follows: 
 ““Payment Amount” means the
amount payable with respect to each vested Phantom Profits Interest Unit upon the applicable Payment Event; provided, however, that, notwithstanding the foregoing, if the Payment Event is due to a Plan Termination, the Payment Amount with respect to
each Grantee shall mean an amount equal to the value of the Grantee’s Phantom Profits Interest Units as of the date of the Plan Termination, subject to adjustment for any earnings (or loss) with respect to such amount during the period
beginning on the Plan Termination and ending on the Plan Termination Distribution Date (as defined in Section 5(b)(iv), below).” 

2. Section 1(i) of the Plan is hereby amended and restated in its entirety to read as follows: 

““Phantom Profits Interest Unit” means the right to receive a payment from the Company in cash or
securities of the Company or one of its affiliates or such other form of payment as the Committee may determine in its sole discretion in an amount equal to the Payment Amount upon the Payment Event as set forth in the applicable Award
Agreement.” 
 3. Section 2(b) of the Plan is hereby amended and restated in its entirety to read as follows: 

“(b) Administrator Authority. The Administrator shall determine (i) the Grantees to receive Awards, (ii) the size
and terms of the Awards, (iii) the time when the Awards will be made, (iv) the applicable Payment Event, (v) the duration of any applicable vesting period, provided that such vesting period shall not be less than four years and that
the Award shall vest ratably over the vesting period, and (vi) the Benchmark Amount with respect to any Award.” 

  
 1 

 4. Section 5(a) of the Plan is hereby amended to add a final sentence that reads as follows:

 “In addition, notwithstanding any other provision of the Plan, a Plan Termination (as defined in Section 16, below) shall
constitute a Payment Event.” 
 5. Section 5(b) of the Plan is hereby amended to add the following new subsection (iv): 

“(iv) Notwithstanding any other provision of the Plan (including, without limitation Sections 5(b)(i)-(iii), above), if the Payment Event
is due to a Plan Termination, the Payment Amount shall be distributed with respect to (a) all Phantom Profits Interest Units that vested prior to or as of the date of the Plan Termination, (b) all Phantom Profits Interest Units that would
otherwise vest between the date of the Plan Termination and the 12-month anniversary of the Plan Termination; provided that, in the event of the termination of the Grantee’s employment prior to an
applicable vesting date during such 12-month period, the Grantee shall forfeit the right to receive the Payment Amount with respect to the Phantom Profits Interest Units that would have vested on such vesting
date, and (c) all Phantom Profits Interest Units that would otherwise vest after the 12-month anniversary of the Plan Termination; provided that, in the event of the termination of the Grantee’s
employment prior to the 12-month anniversary of the Plan Termination, the Grantee shall forfeit the right to receive the Payment Amount with respect to such Phantom Profits Interest Units. Such Payment Amount
shall be distributed to the Grantee on the first business day following the 12-month anniversary of the Plan Termination (the “Plan Termination Distribution Date”); provided that no such
distribution shall be made if the Plan Termination Distribution Date and associated distributions are determined by the Administrator to be proximate to a downturn in the Company’s financial health (within the meaning of Treasury Regulation Section 1.409A-3(j)(4)(ix)(C)) if such distribution would result in additional taxes or penalties to the Grantee under Section 409A of the Code, and in such event the distribution shall be made as soon
thereafter as permissible without penalty under Section 409A of the Code.” 
 6. The following new Section 16 shall be added
to the Plan: 
 “16. Plan Termination 

The Plan shall be terminated (the “Plan Termination”) effective as of the date Bioventus Inc.’s
registration statement on Form S-1 is declared effective, subject to the consummation of the initial public offering of Bioventus Inc. Class A Common Stock (the “IPO”), and in connection
with the Plan Termination distributions shall be made to all eligible Grantees in accordance with Section 5(b)(iv), above. The Plan Termination is intended to comply with Treasury Regulation
Section 1.409A-3(j)(4)(ix)(C) and this amendment and termination shall be interpreted accordingly. Notwithstanding the foregoing, no provision of this amendment and termination shall be interpreted or
construed to transfer any liability for failure to comply with the requirements of Section 409A of the Code from any Grantee or any other individual to the Company or any of its affiliates, employees or agents.” 

  
 2 

 7. The Plan, and all of the rights, privileges, title, interests, liabilities and
obligations of Bioventus LLC under the Phantom Plan, will be assumed by Bioventus Inc. pursuant to that certain Assignment and Assumption Agreement, entered into by and between the Company and Bioventus Inc., effective as of the date set forth
therein. Following such assumption (a) “Company” shall mean Bioventus Inc., (b) “Board” shall mean the Board of Directors of Bioventus Inc., and (c) “Administrator” shall mean the Board of Directors
of Bioventus Inc., and the Plan shall be interpreted accordingly. 
 8. The form of payment to be made to the Grantee shall be determined by
the Administrator in its sole discretion. 
 9. This amendment and termination shall be governed in all respects, including as to validity,
interpretation and effect, by the internal laws of the State of Delaware, without giving effect to the choice of law principles thereof. Except as set forth in this amendment and termination, the terms and conditions of the Plan shall remain in full
force and effect. In accordance with its authority under Section 2 of the Plan, the Administrator has determined that this amendment and termination does not adversely impact the rights of any Grantee under any Award granted to such Grantee
under the Plan. 
 * * * * * * * * 

  
 3 

 Executed as of the first date set forth above. 

 

			
	BIOVENTUS LLC
		
	By:	 	 /s/ Kenneth Reali

		 	Name: Kenneth Reali
		 	Title: Chief Executive Officer

  
 Signature Page to
Amendment to 
 the Bioventus Stock PlanEX-10.50

 Exhibit 10.50 

ASSIGNMENT AND ASSUMPTION AGREEMENT 

This ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”), dated as of February 9, 2021, and effective as of
the Effective Date (defined below), is hereby entered into by and among Bioventus LLC, a Delaware limited liability company (“Assignor”), and Bioventus Inc. (“Assignee”). 

R E C I T A L S: 

WHEREAS, Assignor currently sponsors the Bioventus Stock Plan (previously known as the Bioventus LLC Phantom Profits Interests Plan), as
amended and restated (the “Plan”); 
 WHEREAS, Assignor desires to assign all of its rights, privileges, title,
interests, liabilities and obligations under the Plan and all awards thereunder to Assignee; and 
 WHEREAS, Assignee wishes to accept the
assignment of such rights, privileges, title and interests and to assume such liabilities and obligations. 
 NOW, THEREFORE, in
consideration of the above premises and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 

1. Assignment. Effective as of the date Assignee’s registration statement on Form S-1 is
declared effective (the “Effective Date”), Assignor hereby assigns, conveys and transfers to Assignee all of its present and future rights, title and interests in, to and under the Plan and all awards thereunder. If
Assignee’s registration statement on Form S-1 is not declared effective, this Agreement shall be void ab initio. 

2. Assumption. Effective as of the Effective Date, (a) Assignee hereby accepts the assignment set forth in
Section 1 hereto and assumes any and all liabilities and obligations of Assignor arising under the Plan and all awards thereunder and (b) the Plan shall be maintained by Assignee for the benefit of Employees (as
defined in the Plan) and Employees shall remain the sole persons eligible to participate in the Plan. Following such assumption (a) “Company” shall mean Bioventus Inc., (b) “Board” shall mean the Board of
Directors of Bioventus Inc., and (c) “Administrator” shall mean the Board of Directors of Bioventus Inc., and the Plan shall be interpreted accordingly. 

3. Further Actions. Each party hereto covenants and agrees to make, execute, acknowledge and deliver such further documents and
instruments and to use its reasonable efforts to take such other action as may be reasonably requested by any party hereto to more effectively consummate or perfect the assignments and assumptions contemplated by this Agreement. 

4. Miscellaneous. 
 (a)
This Assignment shall be governed by and construed in accordance with the law of the State of Delaware, without regard to the conflicts of law rules of such state or any other jurisdiction. 

 (b) If any term, provision, covenant or restriction of this Agreement is held by a court of
competent jurisdiction or other governmental authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected,
impaired or invalidated so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a determination, the parties shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. 

(c) This Assignment shall inure to the benefit of Assignee and its successors and assigns, and shall be binding upon Assignor and its
successors and assigns. 
 (d) This Assignment is not intended to, nor shall it, create any rights in or confer any benefits upon any person
other than the parties to this Assignment. 
 (e) This Assignment may be executed in two or more counterparts, each of which shall be deemed
to be an original, but all of which together shall constitute one and the same instrument. Any counterpart may be signed and transmitted by facsimile or Portable Document Format (PDF) with the same force and effect as if such counterpart was an ink-signed original. 
 [SIGNATURE PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the parties hereto have caused this Assignment and Assumption
Agreement to be duly executed as of the day and year first above written. 
  

			
	ASSIGNOR
	
	BIOVENTUS LLC
		
	By:	 	 /s/ Kenneth Reali

		 	Name: Kenneth Reali
		 	Title: Chief Executive Officer
	
	ASSIGNEE
	
	BIOVENTUS INC.
		
	By:	 	 /s/ Kenneth Reali

		 	Name: Kenneth Reali
		 	Title: Chief Executive Officer

 [Signature page to Assignment and Assumption Agreement re: Bioventus Stock Plan]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00320-of-00352.parquet"}]]